BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s): BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

CSE:BIOV - Post by User

BioVaxys Technology Corp. > Roll it back 1 for 20

<< Previous

Bullboard Posts

Next >>

Comment by Appreciation777on Jul 28, 2023 7:39pm

298 Views

Post# 35562659

RE:Roll it back 1 for 20

Great potentiality here for BIOV, once they roll it back. They may not have to do 1 for 20 as there is 105 Million outstanding only I understand and insiders own most of the stock. perhaps 1 for 5, that ratio will shake a lot of the old shareholders, followed by PP at .50 cents with options at .75. AND we could have a home with the latest development news on the way.

<< Previous

Bullboard Posts

Next >>

Dollar Tree CEO Rick Dreiling steps down as discount retailer struggles